Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers

Table 2 Association between ypT stage and ypN status n (%)

Ref.	No. of patients	Neoadjuvant therapy regimen		Time interval1 (wk)	No. of patients with ypT0/T1
		Radiotherapy (Gy)	Chemotherapy		ypN+/ypT0-1	ypN+/ypT2-4
Zmora et al[42]	109	45-50.4	5-Fu	6	4/33 (12.1)	30/61 (49.2)
Read et al[43]	644	20-45	5-Fu	NS	3/87 (3.4)	217/557 (39.0)
Bujko et al[44]	147	5 × 5		1	0/4 (0.0)	69/138 (50.0)
Bujko et al[44]	138	50.4	5-Fu	4-6	2/33 (6.1)	41/101 (40.6)
Pucciarelli et al[45]	235	45-50.4	5-Fu	6-8	3/69 (4.3)	45/166 (27.1)
Tulchinsky et al[46]	101	45	5-Fu	5-7	1/22 (4.5)	29/75 (38.7)
Habr-Gama et al[47]	401	50.4	5-Fu	8	3/25 (10.7)	75/224 (33.5)
Stipa et al[48]	187	50.4	5-Fu	NS	3/44 (6.8)	48/143 (33.6)
Kundel et al[49]	320	45	5-Fu	4-8	3/69 (4.3)	49/222 (22.1)
Gavioli et al[31]	139	50	5-Fu	4	2/34 (5.9)	38/105 (36.2)
Kim et al[50]	282	45	5-Fu	4-8	2/58 (3.4)	85/224 (37.9)
Lindebjerg et al[51]	135	60	5-Fu	8	8/47 (17.0)	32/88 (36.4)
Coco et al[52]	271	NS	NS	NS	3/71 (4.2)	70/200 (35.0)
Total	3109				37/596 (6.2)	828/2304 (35.9)

¹Time interval refers to the time from the end of neoadjuvant therapy to subsequent operation. NS: Not specified; 5-Fu: 5-fluorouracil.